Barclays PLC Sells 198,157 Shares of Hologic, Inc. (NASDAQ:HOLX)

Barclays PLC trimmed its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 27.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 520,074 shares of the medical equipment provider's stock after selling 198,157 shares during the period. Barclays PLC owned about 0.23% of Hologic worth $37,490,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. General Partner Inc. bought a new stake in shares of Hologic in the 4th quarter worth about $26,000. Venturi Wealth Management LLC increased its holdings in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares in the last quarter. Finally, Smithfield Trust Co grew its position in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on HOLX shares. Morgan Stanley lowered their target price on Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Leerink Partnrs cut shares of Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective for the company. in a research report on Monday, February 3rd. Finally, Raymond James reiterated an "outperform" rating and issued a $90.00 price objective (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $84.62.

Hologic Trading Up 0.9 %

Shares of HOLX stock traded up $0.54 on Wednesday, hitting $58.73. The stock had a trading volume of 334,733 shares, compared to its average volume of 1,949,178. The firm has a market cap of $13.18 billion, a P/E ratio of 18.53, a PEG ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a twelve month low of $55.89 and a twelve month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a fifty day moving average price of $61.34 and a two-hundred day moving average price of $70.45.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.